M
Maryalice Stetler-Stevenson
Researcher at National Institutes of Health
Publications - 281
Citations - 24373
Maryalice Stetler-Stevenson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Minimal residual disease & Immunophenotyping. The author has an hindex of 67, co-authored 277 publications receiving 21068 citations. Previous affiliations of Maryalice Stetler-Stevenson include Science Applications International Corporation.
Papers
More filters
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
James N. Kochenderfer,Mark E. Dudley,Steven A. Feldman,Wyndham H. Wilson,David Spaner,Irina Maric,Maryalice Stetler-Stevenson,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,James Chih-Hsin Yang,Udai S. Kammula,Laura Devillier,Robert J. Carpenter,Debbie Ann N. Nathan,Richard A. Morgan,Carolyn M. Laurencot,Steven A. Rosenberg +17 more
TL;DR: Pro adoptive transfer of T cells genetically modified to express an anti-CD19 chimeric Ag receptor (CAR) has great promise to improve the treatment of B-cell malignancies because of a potent ability to eradicate CD19(+) cells in vivo; however, reversible cytokine-associated toxicities occurred after CAR-transduced T-cell infusions.
Journal ArticleDOI
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer,Wyndham H. Wilson,John E. Janik,Mark E. Dudley,Maryalice Stetler-Stevenson,Steven A. Feldman,Irina Maric,Mark Raffeld,Debbie Ann N. Nathan,Brock J. Lanier,Richard A. Morgan,Steven A. Rosenberg +11 more
TL;DR: A patient with advanced follicular lymphoma was treated by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B- cell antigen CD19, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti-CD19-CAR-transduced T cells.
Journal ArticleDOI
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
Terry J. Fry,Nirali N. Shah,Rimas J. Orentas,Maryalice Stetler-Stevenson,Constance M. Yuan,Sneha Ramakrishna,Pamela L. Wolters,Staci Martin,Cindy Delbrook,Bonnie Yates,Haneen Shalabi,Thomas J. Fountaine,Jack F. Shern,Robbie G. Majzner,David F. Stroncek,Marianna Sabatino,Yang Feng,Dimiter S. Dimitrov,Ling Zhang,Sang M. Nguyen,Haiying Qin,Boro Dropulic,Daniel W. Lee,Crystal L. Mackall +23 more
TL;DR: These results are the first to establish the clinical activity of a CD22-CAR in B-all, including leukemia resistant to anti-CD19 immunotherapy, demonstrating potency against B-ALL comparable to that of CD19-CAR at biologically active doses.
Journal ArticleDOI
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile
Adrian Wiestner,Andreas Rosenwald,Todd S. Barry,George E. Wright,R. Eric Davis,Sarah E. Henrickson,Hong Zhao,Rachel E. Ibbotson,Jenny A. Orchard,Zadie Davis,Maryalice Stetler-Stevenson,Mark Raffeld,Diane C. Arthur,Gerald E. Marti,Wyndham H. Wilson,Terry J. Hamblin,David Oscier,Louis M. Staudt +17 more
TL;DR: ZAP-70 expression and IgVH mutation status were comparable in their ability to predict time to treatment requirement following diagnosis, and reverse transcriptase-polymerase chain reaction and immunohistochemical assays for ZAP- 70 expression can be applied clinically and would yield important prognostic information for patients with CLL.